ADVENTRX to Present CoFactor Phase II Data at ASCO Gastrointestinal Cancer Conference
January 17 2006 - 11:00AM
PR Newswire (US)
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) today announced that it will
present time-to-tumor progression, safety and blinded
independently-assessed tumor response results from its Phase II
multi-center CoFactor(TM) clinical trial at the 2006
Gastrointestinal Cancers Symposium. The clinical trial data will be
presented as abstract #461 entitled "5,10-methylenetetrahydrofolic
acid with 5-fluorouracil as first line treatment in metastatic
colorectal cancer: a phase II study" on Saturday, January 28, 2006,
11:30 am - 1:00 pm. The conference is sponsored in part by the
American Society of Clinical Oncology (ASCO) and takes place
January 26-28 in San Francisco. About CoFactor CoFactor (ANX-510)
is a folate-based biomodulator drug being developed to enhance the
activity and reduce associated toxicity of the widely used cancer
chemotherapeutic 5-fluorouracil (5-FU). In comparison to
leucovorin, CoFactor creates more stable binding of the active form
of 5-FU to the target enzyme, thymidylate synthase (TS). CoFactor
bypasses the chemical pathway required by leucovorin to deliver the
active form of folate, allowing 5-FU to work more effectively. This
improves 5-FU performance and lowers toxicity. A Phase IIb
randomized controlled clinical trial is ongoing to evaluate
CoFactor with 5-FU as a first line treatment of metastatic
colorectal cancer. The Company has received clearance under a
special protocol assessment from the US Food and Drug
Administration (FDA) to begin a CoFactor Phase III pivotal clinical
trial for metastatic colorectal cancer, which is currently planned
to begin patient dosing in Q1 2006. About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new technologies for anticancer and
antiviral treatments that surpass the performance and safety of
existing drugs, by addressing significant problems such as drug
metabolism, toxicity, bioavailability and resistance. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024